New drug combo shows promise for Hard-to-Treat ovarian cancer
NCT ID NCT04606914
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing a combination of the targeted drug mirvetuximab soravtansine and the chemotherapy carboplatin as a first treatment for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific marker (folate receptor alpha). About 70 participants will receive the drugs before and after surgery to remove visible tumors. The goal is to see if this approach improves how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mirvetuximab soravtansine (a targeted drug that delivers chemotherapy to cancer cells with a specific marker) combined with carboplatin (a standard chemotherapy)
What this could lead to
If successful, this could offer a more effective first-line treatment option for women with advanced ovarian cancer that has a specific marker (folate receptor alpha).
What could go wrong
This is a small, early-phase (phase 2) study with only 70 participants, so results may not apply to all patients. The drug combination may cause side effects, and it is not yet known if it improves survival compared to standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Allegheny Health Network
RECRUITINGPittsburgh, Pennsylvania, 15224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University
RECRUITINGColumbus, Ohio, 43026, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Alabama at Birmingham Womens & Infants Center
RECRUITINGBirmingham, Alabama, 35233, United States
Contact
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94158, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Minnesota - Masonic Cancer Center
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Mississippi Medical Center
RECRUITINGOxford, Mississippi, 36607, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Oklahoma
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Virginia
RECRUITINGRichmond, Virginia, 23219, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••